U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H30N4O5S.ClH
Molecular Weight 487.013
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACOTIAMIDE HYDROCHLORIDE ANHYDROUS

SMILES

Cl.COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C

InChI

InChIKey=VQEKQYLTAIVCBW-UHFFFAOYSA-N
InChI=1S/C21H30N4O5S.ClH/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26;/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27);1H

HIDE SMILES / InChI
Molecular Formula C21H30N4O5S
Molecular Weight 450.552
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21123674 | https://www.ncbi.nlm.nih.gov/pubmed/10871292 | https://www.astellas.com/en/corporate/news/pdf/130605_1_Eg.pdf

Acotiamide (Acofide(®)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Acofide® is launched in Japan for treating functional dyspepsia.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 3.0 µM [IC50]
Antagonist
2778
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ACOFIDE

Approved Use

Acofide (Acotiamide hydrochloride hydrate) improves gastrointestinal motility and promotes excretion of stomach contents by inhibiting acetylcholinesterase activities. It is usually used for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.

Launch Date

2013
PubMed

PubMed

TitleDatePubMed
[Functional and motor gastrointestinal disorders].
2008 Oct
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.
2008 Sep
Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
2010 Jun
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
2010 Jun
Patents

Patents

JP2011068692A
3

Sample Use Guides

In Vivo Use Guide
In general, for adults, take 1 tablet (100mg of the active ingredient) at a time, 3 times a day before meals.
Route of Administration: Oral
In Vitro Use Guide
Acotiamide (0.3 and 1 uM) significantly enhanced the contraction of guinea pig gastric body strips induced by electrical field stimulation
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:08:14 GMT 2023
Edited
by admin
on Sat Dec 16 06:08:14 GMT 2023
Record UNII
510791NN30
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACOTIAMIDE HYDROCHLORIDE ANHYDROUS
Common Name English
4-THIAZOLECARBOXAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)-, MONOHYDROCHLORIDE
Common Name English
4-THIAZOLECARBOXAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
ACOTIAMIDE HYDROCHLORIDE [MI]
Common Name English
Acotiamide hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID30171717
Created by admin on Sat Dec 16 06:08:14 GMT 2023 , Edited by admin on Sat Dec 16 06:08:14 GMT 2023
PRIMARY
CAS
185104-11-4
Created by admin on Sat Dec 16 06:08:14 GMT 2023 , Edited by admin on Sat Dec 16 06:08:14 GMT 2023
PRIMARY
PUBCHEM
9957090
Created by admin on Sat Dec 16 06:08:14 GMT 2023 , Edited by admin on Sat Dec 16 06:08:14 GMT 2023
PRIMARY
MERCK INDEX
m1383
Created by admin on Sat Dec 16 06:08:14 GMT 2023 , Edited by admin on Sat Dec 16 06:08:14 GMT 2023
PRIMARY Merck Index
FDA UNII
510791NN30
Created by admin on Sat Dec 16 06:08:14 GMT 2023 , Edited by admin on Sat Dec 16 06:08:14 GMT 2023
PRIMARY
Related Record Type Details
Structure of ACOTIAMIDE HYDROCHLORIDE
SOLVATE->ANHYDROUS
Structure of ACOTIAMIDE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ACOTIAMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966